Fourrts

What Fourrts does

Fourrts (India) Laboratories Pvt. Limited is a privately held pharmaceutical company founded in 1977 and headquartered in Chennai, India. The company develops, manufactures, and markets branded generic pharmaceutical and nutraceutical products across 16 therapy areas including gastroenterology, nephrology, urology, respiratory, diabetes, orthopedics, gynecology, and wound care. Fourrts operates through five Indian market divisions (Premiere, Specialist, Gastro, Vibrant, and Herbominerals) plus two international segments (Regulated Markets CMO/CDMO and Emerging Markets). Its portfolio includes patented and first-in-India brands such as Nefrosave (patented Taurine+Acetylcysteine combination), LMontus (world's first levocetirizine+montelukast FDC), PrePro (multi-strain probiotic with 9 strains), and Sucrafil (ranked No. 1 globally in sucralfate therapy). The company employs 2,500 professionals and serves patients across 50+ countries.

The company operates two manufacturing facilities in Chennai: Plant-1 (WHO GMP and ISO 9001:2018 certified) producing tablets, capsules, liquid orals, topical creams, ointments, and medicated toothpaste with capacity of 4 billion tablets, 450 million capsules, 45 million liters of liquids, and 37,500 kg of topical products annually; and Plant-2 (US FDA, UK MHRA, EU GMP, Saudi FDA approved) with 228,000 sq. ft. built-up area, designated as a 100% Export Oriented Unit, producing 4 billion tablets and 350 million capsules annually with 6 granulation suites, 6 compression lines, 4 coating sections, and 9 packaging lines. Plant-2 also offers end-to-end contract manufacturing, formulation development, and tech transfer services to regulated markets.

The company's revenue model is multi-stream: (1) branded generics through field-force sales in India targeting doctors and specialists across five therapy-specific divisions; (2) branded generics exports to 50+ emerging markets across Central Asia, Africa, the Caribbean, and Southeast Asia via 600+ registered product dossiers; (3) CMO/CDMO services for regulated markets (USA, Europe, UK, Canada, Australia, Middle East, LATAM) leveraging Plant-2's FDA/MHRA approvals; and (4) in-licensing and out-licensing opportunities for global partners. The company is family-owned and operated under Chairman and Managing Director S V Veeramani and Joint Managing Director Radha Veeramani, with no disclosed external institutional investor involvement.

Name

Fourrts

Legal name

Fourrts (India) Laboratories Pvt. Limited

Website

https://fourrts.com

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Fourrts is a privately held Chennai-based pharmaceutical company founded in 1977 that manufactures and markets branded generic and nutraceutical products across 16 therapy areas via five Indian divisions and international operations in 50+ countries, serving doctors, specialists, and global CMO/CDMO partners.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Pharmaceutical manufacturing
• Branded generics
• Contract manufacturing
• Nutraceutical products
• Pharmaceutical formulations

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Branded Generics – Indian Market: Fourrts sells branded generic pharmaceutical products across India through five dedicated divisions (Premiere, Specialist, Gastro, Vibrant, Herbominerals) targeting multiple therapy areas including nutraceuticals, diabetes, gastroenterology, nephrology, urology, and respiratory. Products are sold through field sales representatives to doctors and healthcare professionals across India.
2. Contract Manufacturing (CMO/CDMO) – Regulated Markets: Fourrts Plant II (US FDA/UK MHRA/EU GMP approved) offers end-to-end CMO/CDMO services for regulated markets including USA, Europe, UK, Canada, Middle East, LATAM, and Australia. Services include contract manufacturing, formulation development, and tech transfer. The company also holds UK Market Authorizations for multiple generic products and offers in-licensing and out-licensing opportunities.
3. Branded Generics – Emerging Markets: Fourrts exports branded generic pharmaceutical products to over 50 countries including Central Asia, Africa, Caribbean, and Southeast Asia. WHO-GMP audited and registered dossiers for 600+ products across 40+ emerging market countries. Global brand presence in over 20 emerging markets.

Go-to-market motion3 records

Distribution channels7 records

Marketing channels6 records

Core offering

Fourrts manufactures and markets branded generic pharmaceutical and nutraceutical products across 16 therapy areas (gastroenterology, nephrology, urology, respiratory, diabetes, orthopedics, wound care, dermatology, etc.) through five specialized divisions in India (Premiere, Specialist, Gastro, Vibrant, Herbominerals). The company exports branded generics to over 50 countries and offers end-to-end CMO/CDMO services from its US FDA/UK MHRA/EU GMP-approved Plant-2 facility for regulated markets including USA, Europe, UK, Canada, Australia, Middle East, and LATAM.

Product overview

Fourrts is a pharmaceutical company established in 1977, operating as a global player in branded generics with presence in over 50 countries. The company offers an extensive portfolio organized into five Indian market divisions (Premiere Division, Specialist Division, Gastro Division, Vibrant Division, and Herbominerals Division) and two international segments (Regulated Markets and Emerging Markets). Core therapy areas span Nutraceuticals, Respiratory, Probiotics, Dermatology, Gastroenterology, Child Health, Liver Care, Fertility Management, Nephrology, Obstetrics & Gynecology, Orthopedics, Urology, Wound Care, Diabetes & Complications, and Homeopathy. The company operates two manufacturing facilities: Plant-1 (WHO GMP, ISO 9001:2018 certified) and Plant-2 (US FDA, UK MHRA, EU GMP, Saudi FDA approved). Notable flagship brands include Nefrosave for kidney care, Sucrafil O Gel for gastroenterology (Brand of the Year 2017), Fourts B for nutraceuticals, Rejunuron for neurology (first Methylcobalamin in India), LMontus for respiratory (world's first levocetirizine+montelukast FDC), and PrePro for probiotics (first in India). The company also offers CMO/CDMO services through its regulated markets facility.

Differentiator

Problem solved

Functional benefit

Brands

• PrePro: Probiotic brand for gastrointestinal health
• Sucrafil
• Nefrosave
• Rejunuron
• Fourts B
• Metffil
• LMontus
• Gumforte

Products and services

• Sucrafil O Gel Sucralfate USP 500mg with Oxetacaine BP 10mg per 5ml suspension for gastrointestinal disorders. Flagship gastroenterology brand ranked No.1 globally in Sucralfate therapy.
• Nefrosave Patented combination medicine with Taurine 500mg and Acetylcysteine 150mg for delaying progression of chronic kidney disease associated with diabetes and hypertension.
• Fourts B Multivitamin and mineral supplement with vitamins, zinc, selenium, chromium, and amino acids. One of the most prescribed multi-vitamin brands in India.
• Rejunuron India's first Methylcobalamin brand for neuropathy management, available in tablets, capsules, and injections.
• LMontus Levocetirizine 5mg and Montelukast 10mg combination. World's first brand of FDC of levocetirizine and montelukast for asthma and allergic rhinitis.
• PrePro Multi-strain probiotic formulation with Lactobacillus and Bifidobacterium species plus FOS and betaglucan for gut health management. First to introduce Pre and Probiotic in India.
• Mupimet Mupirocin IP 2% for bacterial skin infections, cuts, wounds, and post-surgical infections. Patent pending innovation.
• Comupimet Sterile collagen particles with Mupirocin 2% and Metronidazole 1% for faster healing of chronic wounds, tunnel wounds, bed sores and diabetic foot ulcers.
• Autolyse Papain-based ointment for enzymatic debridement of necrotic tissue, helping removal of slough from wounds.
• Quadrajel Oral gel with Chlorhexidine, Metronidazole, Lignocaine and Menthol for painful oral ulcers.
• Diafoot SB Foot cream with Shea Butter, Allantoin, Urea and Liquid Paraffin for moisturizing and protecting diabetic foot.
• Alafin Alpha Lipoic Acid 600mg for diabetic neuropathy. The only brand in India offering this dosage.
• Albunil Acetylcysteine 150mg and Taurine 500mg combination to prevent microalbuminuria and protect kidneys.
• Ubicar Ubidecarenone 30mg with L-Carnitine 500mg for muscle cramps and myalgia, including pregnancy-induced muscle cramps.
• Tamfil Tamsulosin Hydrochloride 0.4mg in OCAS technology for lower urinary tract symptoms associated with BPH (Benign Prostatic Hyperplasia).
• Pulmoclear Acebrophylline and Acetylcysteine combination. First brand of this FDC for respiratory conditions.
• Allerbio India's first Anti Allergic Probiotic with Lactobacillus Paracasei and Lactobacillus Fermentum for allergy treatment.
• Gumforte Gel Homeopathic dental care gel with Plantago major Q, Calendula officinalis Q, Borax 6x and Kreosotam Q. Leading brand in Homoeopathic Dental Care segment in India.
• Uphold Tadalafil 10mg with Dapoxetine 30mg for premature ejaculation associated with erectile dysfunction.
• Mildfil Tadalafil 5mg for erectile dysfunction management in diabetic patients.
• EDsave Tadalafil 5mg for erectile dysfunction management in diabetic patients.
• KMac Potassium Citrate 1100mg and Magnesium Citrate 375mg combination for prevention of renal stones and burning urination associated with UTI.
• Myofatige Palmitoylethanolamide 150mg with Acetyl L Carnitine 300mg and Vitamin E for neuromuscular pain, muscle fatigue and cramps.
• Tenlifil Teneligliptin 20mg, novel DPP4 inhibitor for Type 2 Diabetes management.
• UbiQ 100 Ubiquinone 100mg with Tribulus terrestris, selenium and arginine for idiopathic male infertility and loss of libido.
• UbiQ 300 Ubiquinone 300mg for oligoasthenospermia associated with male infertility.
• Alsody Alpha Lipoic Acid 600mg with Superoxide Dismutase 140IU for low back pain and chronic neck pain.
• Matreheal Glutamine, L-Arginine, Lysine, Vitamin C, Zinc and Selenium sachet for fracture healing.
• Laxopeg Polyethylene glycol 3350 for constipation. Together with SKUs, ranked No.1 in value in PEG 3350 market.
• CMO/CDMO Contract Manufacturing Services End-to-end contract manufacturing, formulation development, and tech transfer services for pharmaceutical companies in USA, Europe, UK, Canada, Middle East, LATAM, and Australia through US FDA/UK MHRA/EU GMP approved Plant-2 facility. Includes in-licensing and out-licensing opportunities.
• Emerging Markets Branded Generic Exports Branded generic pharmaceutical exports to over 50 countries including Central Asia, Africa, Caribbean, and Southeast Asia. 600+ registered product dossiers across 40+ countries with WHO-GMP audit approvals.

Quantifiable outcome

• Sucrafil O Gel ranked No. 1 globally in Sucralfate therapy
• +8 more outcomes

Named customers8 records

Segments8 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

13 partnerships are on record, tiered minor and core.

• Clinics in Chest Medicine (India) and Leading Hospital Pulmonary DepartmentsminorStrategic or Co-development Partner · 6 May 2025Fourrts collaborated with Clinics in Chest Medicine (India) and pulmonary departments of leading hospitals for a World Asthma Day 2025 Walkathon, raising asthma awareness with department heads, doctors, and postgraduates.
• Women in Nephrology (WIN)minorStrategic or Co-development Partner · 6 April 2025Fourrts collaborated with Women in Nephrology (WIN) to conduct the 'Her Health, Her Power' Women's Kidney Wellness Camp benefiting over 36 women participants with nephrologist consultations.
• Rotary Club of Adyar / Gurupriya Vision Research Foundation (Radhatri Nethralaya Eye Hospital)coreStrategic or Co-development Partner · 21 March 2025Fourrts jointly with Rotary Club of Adyar inaugurated the 'RC ADYAR – ROP EYE SCREENING FOR PRE-TERM BABIES' CSR project by donating a Toyota Rumion seven-seater vehicle to the 'VISION ON WHEELS' project run by Gurupriya Vision Research Foundation to screen pre-term babies for Retinopathy of Prematurity (ROP) via teleophthalmology in rural Tamil Nadu and Andhra Pradesh.
• Various Medical Colleges and HospitalsminorStrategic or Co-development Partner · 13 March 2025Fourrts conducted 400+ health camps across India on World Kidney Day 2025, reaching Mysore KR Hospital, Sree Balaji Medical College, Kilpauk Medical College, and other institutions with microalbuminuria screening using Micral tests.
• iPHEX (India Pharma Expo)minorGTM or Marketing Partner · 28 August 2024Fourrts participated in iPHEX (India Pharma Expo) as an exhibitor showcasing their pharmaceutical products, CMO/CDMO capabilities, and networking with global pharmaceutical industry participants.
• Association for Non-Traditional Employment for Women (ANEW), ChennaicoreStrategic or Co-development Partner · 27 June 2024Fourrts partnered with ANEW Chennai to provide 17 Pink Autos to underprivileged women along with autorickshaw driving training and Public Service Vehicle Badge Driving License support. This women empowerment initiative provides sustainable income through daily financial independence.
• Rotary Club of Aarch City-MadrascoreStrategic or Co-development Partner · 22 June 2023Fourrts partnered with Rotary Club of Aarch City-Madras to provide defibrillators and crash carts to Rajiv Gandhi Government General Hospital (RGGGH), Chennai, and to support child cancer care at Institute of Child Health, Madras Medical College by providing ultrasound scanners and laparoscopic surgical equipment.
• Panchayat Union Primary School, Kandigai & Government Higher Secondary School, AyyapanthangalminorOthers · 19 April 2023Fourrts built two additional classrooms with upgraded infrastructure at Panchayat Union Primary School in Kandigai, and constructed a compound wall, new toilet block, and renovated laboratory at Government Higher Secondary School in Ayyapanthangal, Chennai.
• Wockhardt Foundation, IndiacoreStrategic or Co-development Partner · 14 February 2022Fourrts partnered with Wockhardt Foundation to manage day-to-day operations of hemodialysis units at the Dialysis Centre established at Government Peripheral Hospital, Saidapet. The centre serves underprivileged patients from nearby communities.
• India Literacy ProjectminorOthers · 17 October 2019Fourrts partnered with India Literacy Project to support 42 higher secondary schools in Villiwakkam Block through a one-day teacher training seminar on science kits, career guidance resources distribution, and career planner book distribution by Chairman Mr. S V Veerramani.
• Rotary Club of Adyar / The Rotary FoundationcoreStrategic or Co-development Partner · 15 January 2000Fourrts has partnered with the Rotary Club of Adyar and The Rotary Foundation, New Delhi through multiple CSR initiatives. Contributions include $250,000+ to establish the Rotary Fourrts Medical Centre in Thoraipakkam providing free medical care to 1,000+ patients monthly. Additional projects include Dialysis Centre at Government Peripheral Hospital Saidapet, Mobile Clinic & Vaccination Van for Hindu Mission Hospital, and Orange Vision Centres for eliminating avoidable blindness.
• Clinics in Chest Medicine (India) & Leading Hospital Pulmonary DepartmentsminorStrategic or Co-development PartnerFourrts collaborated with Clinics in Chest Medicine (India) and pulmonary departments of leading hospitals to organize the Breathe Free Walkathon on World Asthma Day 2025, raising asthma awareness with participation from department heads, doctors, and postgraduates.
• Indian Drug Manufacturers' Association (IDMA)minorOthersFourrts provided free medicines through IDMA to the Government of Kerala to support flood-affected victims, extending timely help to communities in crisis.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Cadila Healthcare (Zydus): Larger Indian pharma company with comprehensive branded generics, APIs, biologics, and consumer wellness. Comparable to Fourrts in therapy area breadth and India-market presence, but operates at significantly larger scale across more global markets.

Direct peers

• Ajanta Pharma: Indian pharma with branded generics across India and emerging markets (Africa, Asia). Comparable to Fourrts in export-led emerging markets strategy and proprietary branded formulations focus.
• Emami: Indian healthcare and FMCG company with healthcare products and over-the-counter medications. Comparable in diversified Indian-market healthcare focus and brand-led strategy, though Emami has more FMCG exposure.
• Alembic Pharmaceuticals: Indian pharma company with branded generics in domestic and international markets, including allergy, gastrointestinal, and specialty therapy areas. Comparable to Fourrts in product portfolio structure and emerging markets export strategy.
• TTK Healthcare: Indian healthcare company with multiple divisions across pharma, consumer products, and medical devices. Comparable in multi-division Indian-market structure and therapy area diversification to Fourrts' five-division model.
• Glenmark Pharmaceuticals: Indian-headquartered pharma with branded generics in India, emerging markets, and a strong specialty/innovation pipeline. Comparable to Fourrts in India+emerging markets model and specialty therapy focus, though larger in scale.
• Mankind Pharma: One of India's largest pharma companies by domestic revenue, focused on branded generics across multiple therapeutic categories with strong field-force presence. Highly comparable to Fourrts in terms of Indian-market branded generics strategy and therapy area diversity.
• Unichem Laboratories: Mid-sized Indian pharma with branded generic formulations across multiple therapy areas including GI, cardiovascular, and neurology. Comparable in scale, Indian-market focus, and branded generics portfolio diversity to Fourrts.
• JB Chemicals & Pharmaceuticals: Indian pharma company with branded prescription generics in India and exports to emerging markets. Comparable scale and business model to Fourrts, with similar focus on specialty therapy areas and CMO/CDMO capabilities.
• Micro Labs: Privately-held Indian pharma company with diversified branded generics portfolio across multiple therapy areas. Closely comparable to Fourrts in private ownership structure, India-focused branded generics strategy, and therapy area breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/fourrtsglobal
• Facebookfacebook.com/fourrtsglobal
• LinkedInlinkedin.com/company/fourrts-india-laboratories

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fourrts